There are errors in [Tables 1](#pone-0109231-t001){ref-type="table"}, [2](#pone-0109231-t002){ref-type="table"} and [3](#pone-0109231-t003){ref-type="table"}. In these tables, significant results (p\<0.05) should be in bold typeface. Please see the corrected tables here.

10.1371/journal.pone.0096656.t001

###### Baseline characteristics of the study subjects.

![](pone.0109231.t001){#pone-0109231-t001-1}

  Variable                                            NC (n = 40)    MCI (n = 40)                        p
  -------------------------------------------------- -------------- -------------- ----------------------------------------------
  Age (years)                                          77.8 (4.5)     79.4 (5.3)       0.145 [b](#nt103){ref-type="table-fn"}
  Gender, female                                       33 (82.5)      27 (67.5)        0.121 [d](#nt105){ref-type="table-fn"}
  Education (years)                                    11.4 (4.4)     10.5 (4.4)       0.279 [c](#nt104){ref-type="table-fn"}
  BMI (kg/m^2^)                                        24.1 (3.0)     24.6 (3.2)       0.431 [b](#nt103){ref-type="table-fn"}
  Hypertension                                         21 (52.5)      24 (60.0)        0.499 [d](#nt105){ref-type="table-fn"}
  SBP (mm Hg)                                         134.8 (19.2)   129.0 (17.4)      0.158 [b](#nt103){ref-type="table-fn"}
  DBP (mm Hg)                                          75.2 (8.7)     73.6 (8.3)       0.404 [b](#nt103){ref-type="table-fn"}
  Heart rate (beats/min)                               65.2 (8.7)     69.6 (9.6)     **0.035** [b](#nt103){ref-type="table-fn"}
  Respiratory rate (cycles/min)                        14.0 (2.4)     15.0 (2.8)       0.104 [b](#nt103){ref-type="table-fn"}
  Smoking                                               2 (5.0)        1 (2.5)         1.000 [e](#nt106){ref-type="table-fn"}
  Alcohol (AU/day)                                     1.3 (1.6)      1.3 (1.5)        0.968 [c](#nt104){ref-type="table-fn"}
  Coffee (cups/day)                                    1.5 (1.0)      1.3 (1.1)        0.317 [c](#nt104){ref-type="table-fn"}
  Physical activity (MET-hours/week)                  68.4 (39.3)    57.6 (39.8)       0.144 [c](#nt104){ref-type="table-fn"}
  Family history of premature CAD                       7 (17.5)       7 (17.5)        1.000 [d](#nt105){ref-type="table-fn"}
  Glucose (mg/dl)                                      87.7 (9.8)    91.5 (10.0)       0.107 [b](#nt103){ref-type="table-fn"}
  Total cholesterol (mg/dl)                           222.9 (37.8)   227.0 (33.9)      0.635 [b](#nt103){ref-type="table-fn"}
  LDL cholesterol (mg/dl)                             137.6 (33.0)   139.7 (28.0)      0.768 [b](#nt103){ref-type="table-fn"}
  HDL cholesterol (mg/dl)                             69.2 (20.5)    65.8 (18.2)       0.470 [c](#nt104){ref-type="table-fn"}
  Triglycerides (mg/dl)                               104.0 (32.4)   106.7 (36.4)      0.745 [b](#nt103){ref-type="table-fn"}
  Target organ damage                                                              
  LVH-echocardiography                                 16 (40.0)      20 (50.0)        0.369 [d](#nt105){ref-type="table-fn"}
  Carotid atherosclerosis                                                          
  Thickening (IMT\>0.9 mm)                             35 (87.5)      30 (75.0)        0.152 [d](#nt105){ref-type="table-fn"}
  plaque/s                                             33 (82.5)      29 (72.5)        0.284 [d](#nt105){ref-type="table-fn"}
  Number of medications                                3.3 (1.7)      3.8 (2.2)        0.311 [b](#nt103){ref-type="table-fn"}
  Antihypertensive medications                                                     
  ACE-Is/ARBs                                          16 (40.0)      23 (57.5)        0.117 [d](#nt105){ref-type="table-fn"}
  Diuretics                                             7 (17.5)       9 (22.5)        0.576 [d](#nt105){ref-type="table-fn"}
  CCBs (peripherally-acting)                            3 (7.5)        8 (20.0)        0.105 [d](#nt105){ref-type="table-fn"}
  Psychotropic medications                                                         
  SSRIs                                                 9 (22.5)      13 (32.5)        0.317 [d](#nt105){ref-type="table-fn"}
  Benzodiazepines [a](#nt102){ref-type="table-fn"}      8 (20.0)       7 (17.5)        0.775 [d](#nt105){ref-type="table-fn"}
  BADL score                                           5.5 (0.5)      5.6 (0.6)        0.325 [c](#nt104){ref-type="table-fn"}
  IADL score                                           7.4 (1.2)      6.7 (1.6)      **0.006** [c](#nt104){ref-type="table-fn"}
  MMSE score                                           28.6 (1.0)     26.8 (2.0)    **\<0.001** [b](#nt103){ref-type="table-fn"}
  CIRS-s score                                         1.6 (0.2)      1.4 (0.2)      **0.029** [b](#nt103){ref-type="table-fn"}
  CIRS-m score                                         2.5 (1.3)      1.7 (1.1)      **0.006** [c](#nt104){ref-type="table-fn"}
  STPI-T score                                         19.5 (5.7)     19.6 (5.7)       0.843 [c](#nt104){ref-type="table-fn"}
  GDS-s score                                          3.4 (3.1)      3.2 (2.8)        0.747 [c](#nt104){ref-type="table-fn"}

Continuous variables are expressed as mean (SD), categorical variables are expressed as n (%). Significant results are shown in bold typeface.

Refers to regular use. Intermittent users (n = 2 in each group) were asked to refrain from use in the two days prior to testing;

Student's t-test;

Mann-Whitney's U-test;

Chi-squared test;

Fisher\'s exact test. NC: normal cognition (controls);

MCI: mild cognitive impairment; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; AU: alcohol units (1 AU = 10 g of alcohol); MET: metabolic equivalent (energy expenditure index, 1 MET =  1 kcal•kg^-1^•h^-1^); CAD: coronary artery disease; LDL: low density lipoprotein; HDL: high density lipoprotein; LVH: left ventricular hypertrophy; IMT: intima-media thickness; ACE-Is: angiotensin converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; CCBs: calcium-channel blockers; SSRIs: selective serotonin reuptake inhibitors; BADL: basic activities of daily living (score range 0-6, higher scores indicate greater functional independence); IADL: instrumental activities of daily living (score range 0-8, higher scores indicate greater functional independence); MMSE: mini mental state examination (score range 0-30, higher scores indicate better cognitive function); CIRS-s: cumulative illness rating scale severity (score range 1-5, higher scores indicate greater comorbidity); CIRS-m: cumulative illness rating scale morbidity (score range 0-13, higher scores indicate more severe comorbidity); STPI-T: state trait personality inventory- trait anxiety subscale (score range 10-40, higher scores indicate greater trait anxiety); GDS-s: geriatric depression scale short form (score range 0-15, higher scores indicate greater depressive symptoms).

10.1371/journal.pone.0096656.t002

###### Characteristics of the study subjects during the experimental session.

![](pone.0109231.t002){#pone-0109231-t002-2}

  Variable                                         NC (n = 40)    MCI (n = 40)                       p                        q [d](#nt112){ref-type="table-fn"}
  ----------------------------------------------- -------------- -------------- -------------------------------------------- ------------------------------------
  SBP after 1 min standing (mm Hg)                 134.7 (20.3)   127.2 (18.0)     0.088 [a](#nt109){ref-type="table-fn"}                   0.157
  DBP after 1 min standing (mm Hg)                 82.1 (10.0)    78.1 (10.1)      0.080 [a](#nt109){ref-type="table-fn"}                   0.156
  Heart rate after 1 min standing (beats/min)      71.6 (11.0)    75.7 (11.3)      0.115 [b](#nt110){ref-type="table-fn"}                   0.185
  SBP after 3 min standing (mm Hg)                 137.7 (18.9)   129.0 (16.7)   **0.034** [a](#nt109){ref-type="table-fn"}                 0.092
  DBP after 3 min standing (mm Hg)                 82.1 (10.4)     78.7 (8.5)      0.111 [a](#nt109){ref-type="table-fn"}                   0.185
  Heart rate after 3 min standing (beats/min)       68.8 (9.6)    73.3 (10.0)    **0.047** [a](#nt109){ref-type="table-fn"}                 0.103
  SBP after 5 min standing (mm Hg)                 134.8 (20.5)   128.1 (16.6)     0.115 [a](#nt109){ref-type="table-fn"}                   0.185
  DBP after 5 min standing (mm Hg)                 81.7 (10.1)     78.6 (9.0)      0.150 [a](#nt109){ref-type="table-fn"}                   0.194
  Heart rate after 5 min standing (beats/min)      69.5 (11.3)     73.6 (9.8)      0.085 [a](#nt109){ref-type="table-fn"}                   0.157
  SBP after 10 min standing (mm Hg)                135.2 (21.4)   124.4 (16.0)   **0.012** [a](#nt109){ref-type="table-fn"}               **0.047**
  DBP after 10 min standing (mm Hg)                82.2 (11.2)     78.7 (8.8)    **0.122** [a](#nt109){ref-type="table-fn"}                 0.185
  Heart rate after 10 min standing (beats/min)     70.9 (10.6)     74.5 (9.9)      0.119 [b](#nt110){ref-type="table-fn"}                   0.185
  Orthostatic hypotension                             4 (10)        7 (17.5)       0.330 [c](#nt111){ref-type="table-fn"}                   0.385
  SBP end of paced breathing (mm Hg)               146.0 (19.9)   139.1 (20.5)     0.132 [a](#nt109){ref-type="table-fn"}                   0.185
  DBP end of paced breathing (mm Hg)                84.3 (9.8)    81.6 (10.6)      0.249 [a](#nt109){ref-type="table-fn"}                   0.301
  Heart rate end of paced breathing (beats/min)     57.9 (6.9)     63.7 (8.1)    **0.001** [a](#nt109){ref-type="table-fn"}               **0.018**
  Respiratory rate standing (cycles/min)            14.9 (2.7)     15.9 (3.1)      0.161 [a](#nt109){ref-type="table-fn"}                   0.201
  Δ Respiratory rate (cycles/min)                   0.9 (1.9)      0.9 (1.6)       0.496 [b](#nt110){ref-type="table-fn"}                   0.526
  VAS stress score standing                        33.7 (22.4)    20.4 (20.4)    **0.007** [b](#nt110){ref-type="table-fn"}               **0.041**
  VAS stress score paced breathing                 42.2 (23.6)    28.5 (23.3)    **0.019** [b](#nt110){ref-type="table-fn"}                 0.055

Continuous variables are expressed as mean (SD), categorical variables are expressed as n (%). Significant results are shown in bold typeface.

Student's t-test;

Mann-Whitney's U-test;

Chi-squared test;

correction for multiple testing by means of the Benjamini-Hochberg procedure with a 5% False Discovery Rate (FDR).

NC: normal cognition (controls); MCI: mild cognitive impairment; SBP: systolic blood pressure; DBP: diastolic blood pressure; Δ respiratory rate: respiratory rate standing- respiratory rate baseline; VAS: visual analogue scale (score range 0-100, higher scores indicate greater stress).

10.1371/journal.pone.0096656.t003

###### Power spectral analysis of heart rate variability in the two groups of subjects.

![](pone.0109231.t003){#pone-0109231-t003-3}

  Variable                                      NC (n = 40)    MCI (n = 40)        p        q [b](#nt116){ref-type="table-fn"}   adjusted p [c](#nt117){ref-type="table-fn"}
  -------------------------------------------- -------------- -------------- ------------- ------------------------------------ ---------------------------------------------
  LFn (n.u)                                                                                                                     
  baseline                                      48.7 (18.1)    49.2 (20.0)       0.910                    0.910                 
  standing                                      65.8 (17.0)    52.7 (20.0)     **0.002**                **0.018**                                 **0.009**
  paced breathing                               38.1 (18.0)    49.1 (18.7)     **0.009**                **0.041**                                 **0.006**
  Δ standing                                    17.1 (16.8)     3.6 (25.7)     **0.007**                **0.041**                                 **0.012**
  Δ paced breathing                             -10.6 (20.7)   -0.1 (23.1)     **0.036**                  0.092                 
  HFn (n.u) [a](#nt115){ref-type="table-fn"}                                                                                    
  baseline                                      30.9 (15.7)    27.5 (13.1)       0.430                    0.470                 
  standing                                      18.5 (10.3)    26.2 (14.3)     **0.015**                **0.049**                                 **0.018**
  paced breathing                               47.7 (18.5)    38.6 (17.3)     **0.035**                **0.092**               
  Δ standing                                    -12.5 (14.2)   -1.4 (13.4)     **0.001**                **0.018**                                 **0.003**
  Δ paced breathing                             16.7 (20.0)    11.0 (17.1)       0.374                    0.422                 
  LF/HF [a](#nt115){ref-type="table-fn"}                                                                                        
  baseline                                       2.4 (2.2)      2.7 (2.7)        0.605                    0.623                 
  standing                                       5.2 (3.8)      3.4 (3.3)      **0.003**                **0.021**                                 **0.006**
  paced breathing                                1.2 (1.5)      1.8 (1.5)      **0.014**                **0.049**                                 **0.039**
  Δ standing                                     2.8 (2.6)      0.7 (3.0)     **\<0.001**               **0.004**                                **\<0.001**
  Δ paced breathing                              -1.2 (2.0)     -0.9 (2.8)       0.075                    0.154                 

HRV indices, expressed as mean (SD), in baseline conditions and during and in response to (Δ) provocative tests (active standing, paced breathing). Significant results are shown in bold typeface.

statistical analyses performed on log ~10~ - transformed variable;

correction for multiple testing by means of the Benjamini-Hochberg procedure with a 5% False Discovery Rate (FDR);

adjustment for potential confounders by means of multiple linear regression (see text for details).

NC: normal cognition (controls); MCI: mild cognitive impairment; n.u.: normalized units; LFn: low frequency power (normalized); HFn: high frequency power (normalized); LF/HF: LF to HF ratio; Δ standing: standing HRV index - baseline HRV index; Δ paced breathing: paced breathing HRV index - baseline HRV index.
